Search results for Bioa

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

BioAge Reports Positive Phase 1 Data for BGE-102

BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeti...

Coalition of Biotechnology Companies Launch American Biotech Innovation Alliance

On May 5, 2025, a coalition of U.S. biotechnology companies announced the launch of the American Biotech Innovation Alliance (ABIA). ABIA states that it will “focus on a shared obj...

Biotissue

Biotissue Anonymous (not verified) Sat, 04/11/2026 - 05:03 field_thread_url https://cafepharma.com/boards/threads/biotissue.543479/ boar...

Bota Biosciences Launches SAION AI Platform for Bio-Manufacturing

Bota Biosciences has launched SAION AI, a physical AI platform that connects cognition, orchestration, and execution to automate bio-manufacturing, reducing strain development from...

Zenas BioPharma's Key Milestones And Market Context: Holding Through The BLA

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

Before AI Meets Your Biobank: Five Must-Do Steps for Research Institutions

This is the first in a series of blog posts focused on AI and clinical trials/research space, highlighting topics to be discussed at the upcoming BIO International convention on Ju...

BridgeBio

BridgeBio Anonymous (not verified) Mon, 05/11/2026 - 11:23 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...

Jade Biosciences: Caution Advised Before Clinical Trial Results

BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS

After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses.

BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an inflammasome linked to a variety of health conditions. 

NJ Bio Inc., Ajinomoto Bio‑Pharma Services agree to collaborate to bolster support for antibody-drug conjugate developme...

NJ Bio Inc., a provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services, a biopharmaceutical manufacturing services and platform technologie...

BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows

BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared intelligence platform”...

Bio-Rad (BIO) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. DATEThursday, July 31, 2025 at 5 p.m. ETCALL PARTICIPANTSChief Executive Officer — Norman D. SchwartzPresident and Chief Operating Officer — Jonatha...

Parse Biosciences and bit.bio Announce Landmark Alliance

This Parse Biosciences and bit.bio alliance combines single-cell RNA sequencing and causal transcriptomics to map transcription factor-driven cell identity, enabling improved disea...

Biocon Launches Denosumab Biosimilars Bosayaâ„¢ / Aukelsoâ„¢ in the United States

On April 7, 2026, Biocon announced the U.S. commercial launch of Bosaya™ / Aukelso™ (denosumab-kyqq), biosimilars of Amgen’s Prolia® / Xgeva® (denosumab)....By: Venable L...

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal admin Tue, 05/12/2026 - 12:10 Big deals lead the way today, with a massive BMS partners...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

AAAbio Introduces High-Specificity Anti-MYCT1 Antibody to Advance Cancer and Gene Regulation Research

AAAbio has launched a highly specific anti-MYCT1 antibody to support cancer and gene regulation research. Designed for techniques such as Western blot, ELISA, and flow cytometry, i...

The Biologics Wake-Up Call Nobody Wanted to Give

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Bio-Composite Materials Market: Regional Analysis and Future Prospects

The bio-composite materials market is witnessing rapid growth as industries shift toward sustainable and eco-friendly alternatives to conventional materials. Bio-composites, made f...